Prostate Cancer - Results from #1340

Low PSA radiographic disease progression on C11-choline PET. February 20, 2024

Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition. February 20, 2024

Quantitative calibration of Tb-161 SPECT/CT in view of personalised dosimetry assessment studies. February 20, 2024

Prostate Cancer Screening Uptake in Transgender Women. February 19, 2024

Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy. February 19, 2024

PI-RADS Upgrading Rules: Impact on Prostate Cancer Detection and Biopsy Avoidance of MRI-Directed Diagnostic Pathways. February 19, 2024

Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer treatments. February 19, 2024

Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy. February 19, 2024

A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. February 16, 2024

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong S February 16, 2024

eHealth literacy in prostate cancer: A systematic review. February 16, 2024

The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance. February 16, 2024

Novel hormonal therapy versus standard of care-A registry-based comparative effectiveness evaluation for mCRPC-patients. February 16, 2024

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. February 16, 2024

Initial COBRA Results: Clarity’s SAR-bisPSMA Is Safe and Highly Effective in Detecting Tumours in Prostate Cancer Patients. Phase 3 Planning Underway. February 15, 2024

ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature. February 15, 2024

Understanding Spatial Correlation Between Multiparametric MRI Performance and Prostate Cancer. February 15, 2024

Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care. February 15, 2024

Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. February 15, 2024

Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis. February 15, 2024

Page 68 of 1436